| Bioactivity | LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM)[1]. |
| Target | EC50：7 nM (human GPR40), 1 nM (mouse GPR40), 3 nM (rat GPR40) |
| Name | LY2922470 |
| CAS | 1423018-12-5 |
| Formula | C28H29NO4S |
| Molar Mass | 475.60 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Hamdouchi C, et al. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916. |
LY2922470
CAS: 1423018-12-5 F: C28H29NO4S W: 475.60
LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC50s o
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.